International Journal of Healthcare Sciences ISSN 2348-5728 (Online) Vol. 10, Issue 1, pp: (90-99), Month: April 2022 - September 2022, Available at: www.researchpublish.com
Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients Yasir.A.Ahmed1*, Ayeed Marfo AlEnizi2, Mansour Farhan AlEnizi3, Fahad Mohammed AlWallan4 1*
Corresponding Author, Senior Lab Tech, PCLMA, KFMC, Riyadh, Saudi Arabia 2 3
Lab Tech I, PCLMA, KFMC, Riyadh, Saudi Arabia
Medical Technologist II, PCLMA, KFMC, Riyadh, Saudi Arabia 4
Senior Lab Tech, PCLMA, KFMC, Riyadh, Saudi Arabia
Pathology and Clinical Laboratory Medicine Administration (PCLMA), King Fahad Medical City, Second Central Healthcare Cluster (C2), Riyadh 11525 P.O. Box 59046, Kingdom of Saudi Arabia. DOI: https://doi.org/10.5281/zenodo.6771809
Published Date: 28-June-2022
Abstract: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease in 2019 (COVID-19) which rapidly evolved from an outbreak in Wuhan, China into a pandemic that has resulted in over millions of infections and over hundreds of thousands of mortalities worldwide. Various coagulopathies have been reported in association with COVID-19, including disseminated intravascular coagulation (DIC), sepsis-induced coagulopathy (SIC), local microthrombi, venous thromboembolism (VTE), arterial thrombotic complications, and thrombo-inflammation. There is a plethora of publications and conflicting data on hematological and hemostatic derangements in COVID-19 with some data suggesting the link to disease progress, severity and/or mortality. There is also growing evidence of potentially useful clinical biomarkers to predict COVID-19 progression and disease outcomes. Of those, a link between thrombocytopenia and COVID-19 severity or mortality was suggested. In this opinion report, we examine the published evidence of hematological and hemostatic laboratory derangements in COVID-19 and the interrelated SARS-CoV-2 induced inflammation. Keywords: biochemistry; new coronary pneumonia; hematology; SARS-CoV-2.
1. INTRODUCTION Along with the vital function for diagnosing excessive acute breathing syndrome coronavirus 2 (SARS-CoV-2) contamination and for assessing the presence and volume of an immune reaction in opposition to the virus, laboratory medication makes a vital contribution in the direction of chance stratification and tracking of inflamed patients. Whilst “routine” hematology and biochemistry assessments aren't unique sufficient to diagnose SARS-CoV-2 contamination, they play a function in several components of the coronavirus disorder 2019 (COVID-19) care pathway, along with affected person control and prognosis. This report through the Pathology and Clinical Laboratory Medicine on COVID-19 presents steering on: (A) scientific indicators for testing, (B) suggestions for check choice and interpretation, (C) issues in check interpretation, and (D) present day obstacles of biochemical/hematological tracking of COVID-19 patients.
2. MATERIAL AND METHOD A. Role of the laboratory in the assessment of biochemical parameters in COVID-19 patients Laboratory tests validated for SARS-CoV-2 are crucial for the timely management of COVID-19 because they support the clinical decision-making process for controlling infections and detecting asymptomatic cases. This expedites speedy isolation, adequate treatment and consequently reduces contagion rates.
Page | 90 Research Publish Journals